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1. Introduction
The amyloidoses comprise a spectrum of diseases caused by the systemic or localised depo‐
sition of characteristic fibrillar material, termed amyloid fibrils [1]. These deposits can be
found in various organs and tissues throughout the body [1]. Each amyloidosis is classified
according to the chemical nature of the protein that forms the initial amyloid fibril deposit
(Table 1). Amyloid fibrils are ubiquitous structures that are rich in cross β-sheets and typi‐
cally have a fibrillar morphology, which can vary in length and diameter [1]. Amyloid fibrils
are detected in vitro and in vivo using specific-binding molecules, namely Congo Red [1], thi‐
ophene derivatives [2] and Thioflavin-S and T [1]. The most common amyloidoses are Alz‐
heimer’s and Parkinson’s disease and type 2 diabetes, in which amyloid fibrils are found
deposited in the central nervous system and in beta cells from the pancreas, respectively [1].
This chapter will cover the transthyretin (TTR)-related amyloidoses, a group of diseases that
roughly affects approximately 8,000-10,000 people worldwide [3]. These amyloidoses are
caused by the aggregation of TTR, an amyloidogenic protein that can give rise to amyloid
fibrils [4].
Transthyretin (TTR) was first discovered in the cerebrospinal fluid (CSF) in 1942 [5, 6] and
then sequenced in 1984 [7], receiving the name prealbumin because of its electrophoretic mi‐
gration pattern compared to albumin. Afterwards, aiming to better describe its functionality,
its name was changed to transthyretin- the transporter of thyroxine (T4) and retinol [5]. TTR
transports retinol through binding to retinol-binding protein (RBP) and T4 due to the forma‐
tion of a hydrophobic channel, which exists only when TTR is tetrameric (Figure 1). Al‐
© 2013 Azevedo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
though its function may vary, TTR is highly conserved from humans to bacteria [8]. TTR is a
55 kDa homotetrameric protein predominantly synthesised by the liver and choroid plexus,
which is located in the brain. Although TTR is known primarily as a transporter, emerging
evidence has demonstrated that TTR can also act as a protease [9] and a neuroprotective
molecule [10].
Table 1. Amyloidogenic proteins and tissues affected in human amyloidoses. Adapted from Hamilton and Benson,
2001.
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The  crystallographic  structure  of  human TTR,  which  was  solved  in  1971  [11],  revealed
that  each  TTR  monomer  is  composed  of  127  amino  acid  residues,  forming  8  β-strands
named from A-H, which are arranged in a β-sandwich of two four-stranded β-sheets and
one small α-helix found between β-strands E and F [11, 12]. TTR monomers interact via
hydrogen bonds between the antiparallel, adjacent β-strands H-H’ and F-F’ to form a di‐
meric species.  The two dimers (A-B and C-D) predominantly form the tetramer through
hydrophobic contacts between the residues of the A-B and G-H loops. The tetramer forms
a central hydrophobic pocket (T4 channel) with two binding sites for hormones [11, 12].
Each TTR monomer contains one cysteine residue at position 10 and two tryptophan resi‐
dues at positions 41 and 79,  which can be used as a tool for monitoring TTR unfolding
[13].  Many groups have studied the structure of TTR and its aggregation process to un‐
derstand  the  triggering  factors  that  favour  TTR  aggregation,  which  occurs  in  a  non-
nucleated manner that is known as a downhill polymerisation reaction because tetramer
dissociation into monomers is the rate-liming step of the aggregation reaction [14]. Based
on this model,  many studies have focused on developing effective and selective TTR li‐
gands that can prevent TTR dissociation and aggregation [15].
Figure 1. X-ray structure of Transthyretin. TTR is a homotetrameric protein composed of four monomers of 127 amino
acids. Structurally, in its native state, TTR contains eight stands (A-H) and a small α-helix. The contacts between the
dimers form two hydrophobic pockets where T4 binds (T4 channel). As shown in red, each monomer contains one
small α-helix and eight β-strands (CBEF and DAGH). Adapted from a model; PDB code 1DVQ.
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Thus, in the present review, we aim to appraise the literature related to TTR aggregation
and focus on the contribution of the thermodynamics and structural aspects related to tet‐
ramer dissociation and monomer unfolding, which appears to be the basis for TTR amyloid
formation.
2. TTR-related amyloidoses
The TTR gene,  which is  located on chromosome 18 at  position 12.1 [16],  presents many
polymorphisms, except for one deletion, leading to over 80 amino acid substitutions in the
TTR polypeptide sequence [16]. Many TTR variants, such as V30M and L55P, are associat‐
ed with familial amyloidotic polyneuropathy (FAP), a lethal autosomal dominant disorder
in which mutant forms of TTR aggregate to form amyloid fibrils that deposit in tissues,
especially the peripheral nervous system (PNS). These amyloid deposits are predominant‐
ly composed of intact or fragmented TTR in the form of fibrillar species that progressively
accumulate [16, 17].  The initial symptom is typically a sensory peripheral neuropathy in
the lower limbs, with pain and severely affected temperature sensation and later followed
by motor impairments [17]. Most patients with FAP have early and severe impairment of
the autonomic nervous system, commonly manifested by dyshidrosis,  sexual  impotence,
alternating diarrhoea and constipation, orthostatic hypotension, and urinary incontinence
[17-19].  The disease onset typically depends on the mutation and the ethnic background
of each patient and begins at  approximately the third or fourth decade of life,  although
there are many cases in which the disease onset occurs later in life [17-19].  Not all  TTR
variant gene carriers develop FAP, indicating that other factors must be involved in the
development of clinical symptoms [19].
Not only are most TTR mutants prone to aggregation, wild-type TTR (wt-TTR) possesses an
inherent, although low, potential to undergo aggregation and form amyloid fibrils (predom‐
inantly in the heart). Hence, it is estimated that approximately 25% of the world population
over 80 years old presents some cardiac amyloid deposits composed of wt-TTR [20]. This
form of TTR amyloidosis is known as senile systemic amyloidosis (SSA). SSA patients typi‐
cally present with congestive heart failure and arrhythmia [20, 21]. Recently, it was demon‐
strated that wt-TTR can aggregate in many tendons and ligaments in aged individuals [22].
Interestingly, among all patients who exhibit SSA symptoms, the male gender predomi‐
nates, suggesting that gender is a significant disease modifier [20, 22].
Some mutations of TTR, such as V122I, have also been associated with cardiac amyloidosis
and are frequently found among African descendants, even though the age of onset varies
significantly among patients [23]. This form of TTR-related amyloidosis is termed familial
amyloid cardiomyopathy (FAC). FAC symptoms comprise an increase in ventricular wall
thickness and an increase in parietal stiffness, which leads to a precipitous increase in ven‐
tricular pressure [23, 24].
Although rare, another form of TTR amyloidosis has been described as predominantly af‐
fecting the central nervous system and is, therefore, known as central nervous system amy‐
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loidosis (CNSA) or oculoleptomeningeal amyloidosis (OA) [25]. Approximately 13 different
mutations, such as D18G and A25T, have been associated with the development of CNSA in
humans [25, 26]. This form of amyloidosis is believed to occur due to the high instability of
TTR mutants, leading to protein degradation by the endoplasmic reticulum-associated deg‐
radation (ERAD) pathway in hepatocytes and preferential secretion by the choroid plexus
epithelium [27]. This preferential secretion by the choroid plexus is believed to be caused by
a higher concentration of T4, which when bound to TTR stabilises the tetramer and favours
its secretion by choroid plexus cells [27]. The age of onset is approximately the fourth to fifth
decade of life, and amyloid accumulation typically occurs in brain vessels and leptomening‐
es, predominantly leading to subarachnoideal bleeding [25]. Some affected individuals may
also develop hydrocephalus with increased CSF pressure and relatively high CSF protein
levels [25]. Leptomeningeal involvement can extend down to the spinal cord, leading to
symptoms related to spinal cord or spinal nerve compression [25]. Most patients have little,
if any, systemic amyloid deposition. In addition to CNS deposits, TTR amyloid fibrils can
also accumulate in the eye vitreous humour, leading to blindness [25].
3. Therapies for TTR-related amyloidoses: When and where to inhibit
aggregation?
The treatment for TTR-related amyloidoses varies according to the symptoms presented by
the patient (cardiac, autonomic or central). Currently, FAP is the only form of TTR-related
amyloidoses that has a treatment, which is orthotopic liver transplantation (OLT) [28]. Al‐
though a treatment exists, some patients have displayed disease progression after OLT,
which has been shown to be due to continued amyloid formation from wt-TTR and is espe‐
cially true in patients with active FAC symptoms [28, 29]. In addition, after OLT, some pa‐
tients develop CNSA symptoms [30, 31] due to the production of mutant TTR by the
choroid plexus. Another problem related to OLT therapy is that this procedure is also
known as “domino liver transplantation”, in which the liver of the FAP patient is transplant‐
ed into a non-FAP patient. However, the non-FAP liver receptors develop FAP symptoms in
less than 5 years and not later in life as expected [32]. These phenomena suggest that OLT
therapy is possible but that it is not a fully effective and safe procedure. In addition, for FAC
or SSA patients, heart transplantations have only been performed successfully worldwide in
a few patients presenting cardiac amyloidosis [33]. In summary, these clinical data empha‐
sise the importance of developing new therapies for TTR-related amyloidosis.
4. TTR-stabilisers: A new and powerful approach to stop TTR
aggregation
TTR can bind a variety of molecules, from small hydrophobic compounds to large glycosa‐
minoglycans, with great flexibility [15]. As mentioned before, TTR is composed of four iden‐
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tical monomeric subunits that assemble around a central channel; therefore, the tetramer
possesses a molecular symmetry with two hormone-binding sites per tetramer (T4 channel).
Under physiological conditions, only one of the hormone-binding sites of the T4 channel is
occupied by T4 [34]. However, hormone binding is governed by a phenomenon termed neg‐
ative cooperativity, in which the binding of T4 to the second binding site reduces the hor‐
mone-binding affinity of the first hormone-binding site [15, 34]. The fact that TTR is not the
only T4 transporter in the human body [34] and that unbound T4 concentrations in blood
are very low (less than 0.1 μM, 34) agree with the fact that most TTR in vivo does not have
T4 bound to its two binding sites. This information has made it possible to design a novel
therapy using small molecules that bind to the T4 channel with high affinity and reduce TTR
aggregation.
Miroy et al. have shown that the binding of T4 itself stabilises the TTR tetramer and con‐
sequently inhibits amyloid formation [35].  Since then, many pharmacological agents and
natural  products,  such  as  plant  flavonoids,  nonsteroidal  anti-inflammatory  drugs
(NSAIDs), and inotropic bipyridines, have been tested, and these agents have been dem‐
onstrated to be strong competitors for T4 binding to TTR and even possess higher binding
affinities than T4 [15, 36, 37]. Interestingly, many of these small molecules share structural
similarities with T4, typically presenting one or more aromatic rings. X-ray crystallograph‐
ic studies have demonstrated that these compounds bind to the TTR hydrophobic chan‐
nel,  similarly  to  T4,  due  to  the  hydrophobic  properties  of  the  compounds  [15,  36].  As
observed for T4 and even RBP, as mentioned above, the binding of NSAIDs to TTR is typ‐
ically negatively cooperative. However,  depending on the ligand, this cooperativity may
change.  The  currently  tested  NSAIDS include  diclofenac,  diflunisal  and flufenamic  acid
[15, 36-39]. Interestingly, the first two compounds are currently approved by the Food and
Drug Administration (FDA) for the treatment of other pathological conditions. Structural
data for TTR complexed with flufenamic acid and diflunisal demonstrate that these com‐
pounds  mediate  hydrophobic  and  hydrogen  bond  interactions  between  the  subunits,
which stabilise tetrameric TTR [36, 38, 39]. The detailed comparisons of several structures
of apo TTR (native TTR) and TTR complexes with small molecules provide insights into
the mechanism of ligand-induced conformational changes on ligand binding [40, 41]. Al‐
though promising, the chronic use of NSAIDS has been correlated with dyspepsia symp‐
toms, small intestine bleeding and ulcers [42].
Natural  polyphenols  (curcumin  and  epigallocatechin  gallate)  and  flavonoids  (quercetin
and chrisin) have also been successful in inhibiting wt- and V30M TTR aggregation under
acidic conditions [43, 44]. Genistein, an isoflavone compound, is also able to inhibit TTR
fibril formation by stabilising the native tetramer [45]. Interestingly, both flavonoids and
genistein interact with Lys15, Ser117 and Thr119, enhancing tetramer stability [44, 45] and
implicating these  amino acids  in  preventing TTR aggregation.  In  addition,  a  TTR point
mutation (Thr119Met) has been demonstrated to be highly stable to denaturising agents
[46], corroborating the idea that the amino acids around the hormone-binding sites aide in
tetramer stabilisation.
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Recently, a new TTR-stabilising drug, Tafamidis, was approved for use in Europe. This class
of compounds functions by preventing the formation of amyloid fibrils, retaining the native
tetrameric state of TTR [15, 47, 48]. This mode of action is possible because the most accept‐
ed theory regarding amyloid fibril formation is that TTR tetramers need to dissociate to a
partially folded monomer, which then rapidly self-assembles to give rise to soluble oligomer
intermediates before reaching the amyloid state [12].
There are many studies introducing the use of TTR-stabilising drugs or antisense oligonu‐
cleotides (ASO) as new, more effective therapies against TTR amyloidosis. There is currently
an on-going trial to test the efficacy of using ASO specifically to target TTR in FAP patients
and its safety in healthy subjects [ISIS pharmaceuticals, ISI-TTRrx, 49]. The rationale behind
ASO therapy and other small interfering RNA (siRNA) therapies [49-51] is that these oligo‐
nucleotides interfere with TTR production in the liver and choroid plexus, inhibiting its pro‐
duction and, therefore, its deposition as amyloid fibrils [49, 50, 52]. Data have shown that
RNA interference techniques have been successful; however, this technique may still be un‐
successful for dealing with old, existing amyloid deposits.
As mentioned above, the use of various compounds as TTR-stabilisers relies on the hypothe‐
sis that TTR needs to dissociate to form fibrils (Figure 2). Although there is evidence sup‐
porting this hypothesis, our group has shown that a cycle of compression-decompression
using high hydrostatic pressure (HHP) is able to produce an altered wt-TTR species (T4*)
that remains tetrameric and that undergoes aggregation under mild acidic conditions (pH
5-5.6), where untreated wt-TTR remains soluble [53] (Figure 2).
Figure 2. Transthyretin (TTR) amyloid cascade. TTR maintains a tetramer to monomer dissociation rate, normally
forming folded monomers. These monomers can partially unfold due to point mutations, acidic conditions, metals,
glycosaminoglycans (GAGs), anionic lipids, high hydrostatic pressure (HHP) and posttranslational modifications. This
unfolded monomer is prone to aggregation, forming prefibrillar species such as oligomers and, consequently, mature
amyloid fibrils. In addition, the alternatively folded tetramers formed during a compression-decompression cycle of
HHP can aggregate either directly or after dissociating into monomers.
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An alternative way to approach this problem is to design drugs that disrupt existing amy‐
loid fibrils. To this end, another class of molecules known as tetracyclines, such as doxycy‐
cline, is able to interfere with TTR fibrillogenesis in vitro [54], disrupting TTR fibrils.
Interestingly, these molecules do not act as inhibitors of TTR fibril formation; however, these
molecules disrupt fibrils [54]. The in vivo use of doxycycline in a murine FAP model exhibits
beneficial effects [54], suggesting that this alternative approach may be as effective as the
use of TTR stabilisers. However, it is unclear whether the products of fibril breakdown are
toxic. The anthracycline compound described by Palha et al., which is known as 4’-deoxi-4’-
iododoxorubicina (IDOX) and which has been used in the treatment of patients diagnosed
with monoclonal immunoglobulin light chain (AL) amyloidosis [55], is able to efficiently
disrupt TTR amyloid fibrils into amorphous aggregates [56]. Although IDOX displayed
promising effects, it was later demonstrated that IDOX is cardiotoxic and is not indicated for
use for that reason [57]. However, this new class of compounds has provided a new way of
understanding TTR pathogenesis and helped to design new and clinically safer fibril-dis‐
rupting drugs.
5. Why TTR aggregates?
Although restricted to a single amino acid substitution, TTR mutations may significantly al‐
ter the kinetics of TTR aggregation [27]. In trying to understand which features of TTR mu‐
tants are responsible for its altered amyloidogenicity, a large amount of crystallographic
data has been collected by different groups worldwide. Unfortunately, the conclusion
reached was that there was no significant deviation in TTR structure. The only exception to
this conclusion was that there were significant deviations for the positions at which the ami‐
no acid substitutions took place [58]. However, these single deviations were not significant
enough to account for the variability in TTR mutation aggressiveness. Although TTR muta‐
tions do not significantly alter the tetrameric structure compared to wt-TTR [58], a single
amino acid substitution is enough to alter the thermodynamic stability and rate of dissocia‐
tion of the tetramer [27]. Many in vitro studies using chaotropic agents such as urea or gua‐
nidine chloride and HHP have revealed that thermodynamic stability and the rate of
tetramer dissociation links certain TTR mutations to variant amyloidogenicity. In one study,
Sekijima et al. conducted a global energetic analysis of 23 disease-associated TTR mutants,
observing that the rate of tetramer dissociation and the thermodynamic stability in increas‐
ing concentrations of urea predicted the aggressiveness of the mutants [27]. Our group has
collected supporting data concerning the latter hypothesis that the amyloidogenic mutants
A25T and L55P, which exhibit an aggressive phenotype, have lower thermodynamic stabili‐
ties than wt-TTR [59, 60]. In addition, we have demonstrated that other amyloidogenic mu‐
tants with exacerbated profiles of aggregation and with high tetramer dissociation rates,
when HHP is applied, are typically associated with the development of clinically severe
FAP [60]. These studies have been corroborated by Hammarstrom et al. [46], who observed
that one particular TTR mutation, T119M, which is clinically associated with a phenomenon
known as trans-suppression, dissociated at a 40-fold slower rate than wt-TTR. These dissoci‐
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ation rates allow this mutant to be significantly more stable than any of the other described
mutants and highly resistant to high urea concentrations for long periods of time [27, 46].
Indeed, this mutation clinically induces trans-suppression, a phenomenon where a patient
bearing the V30M mutation, an amyloidogenic variant associated with FAP, along with the
T119M mutation does not develop amyloid deposits and, therefore, has no FAP symptoms
[46]. In fact, it was later demonstrated that the TTR tetramers that circulated in this patient’s
bloodstream were hybrids composed of T119M and V30M monomers [46]. These hybrid tet‐
ramers gained the characteristic stability of T119M, which overcame the characteristic insta‐
bility of V30M, and these properties allowed the hybrid tetramers to remain intact and
prevent the formation of amyloid fibrils [46].
In addition, the X-ray crystallographic data for the V30M variant, which is also involved in
FAP, revealed a perturbation of the β-sheets, which led to a distortion of the T4-binding
channel that weakens the hormone interactions [61]. The X-ray structure of another highly
amyloidogenic mutant, known as L55P, revealed a disruption of the hydrogen bonds be‐
tween strands D and A, which produces different interface contacts and, in contrast to what
has been mentioned previously, results in eight monomers that have different packing ar‐
rangements than that described for wt-TTR [62]. In addition, the highly amyloidogenic, yet
engineered, triple mutant G53S/E54D/L55S reveals a new conformation with a novel β-slip
conformation, which results in the shift of three residues in strand D and places Leu58 at the
position occupied by Leu55. This new conformation impacts the binding interactions with
retinol-binding protein [63]. Together, these data lead us to believe that mutations that influ‐
ence the unfolding of monomers create species that are prone to aggregation. The contribu‐
tion of the inserted amino acid does not alter the overall structure of the protein but may be
capable of interfering with the aggressiveness of the disease, of impacting tetramer stability
and dissociation rates and of directing the aggregate to specific tissues such as the peripher‐
al nerves, heart, and meninges.
Although these structural alterations may predict TTR amyloidogenicity, some studies have
also shown that because of the presence of cysteine residues (4 per tetramer), TTR is more
prone to be posttranslationally modified, such as by S-thiolation and S-sulphonation [64, 65],
which have been shown to affect TTR amyloidogenicity. In addition, only 5-15% of circulating
TTR is free of posttranslational modifications [66]. One study has also shown that the interac‐
tion of TTR with anionic lipids and cholesterol might accelerate the aggregation process [67].
TTR aggregation, especially in vivo, does not occur without additional proteins. In fact, in
addition to the factors mentioned above, there are many other factors involved in TTR ag‐
gregation. The TTR amyloid fibrils from FAP patient deposits and nearly all amyloid fibrils
in vivo are found to be co-aggregated with many other molecules such as serum amyloid P
(SAP), heparan sulphate, and metalloproteinases, which makes it even more difficult to ana‐
lyse which one of these molecules actually contributes to TTR aggregation and clearance in
vivo and in vitro [1, 68-70]. Among the various molecules that co-aggregate with TTR, glyco‐
saminoglycans (GAGs) are able to accelerate the aggregation of TTR in vitro, and this phe‐
nomenon is dependent on the degree of GAG sulphation [69]. Because the GAG
composition and concentrations vary among different tissues, this fact might partly explain
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the specificity of these aggregates for certain tissues [69]. Murakami et al. has described the
effect of augmented levels of SAP in the deposition of TTR fibrils in the tissue of TTR trans‐
genic mice [70]. Although SAP was found to be associated with TTR deposits, their findings
suggest that SAP does not affect the severity or onset of TTR deposition into the gastrointes‐
tinal tract of mice [70]. Our group has recently shown that the TTR fibrils formed from a
CNSA-related mutant, A25T, are able to sequester a diversity of molecules from human CSF
during aggregation [59]. Many of these molecules are associated with inflammation and co‐
agulation, suggesting that in vivo these pathways may also contribute to TTR-related amy‐
loidosis. Indeed, in many of the amyloidotic tissues from FAP patients, an upregulation of
inflammation-associated molecules such as inducible nitric oxide synthase (iNOS), IL-1β
and TNF-α [68] has been found. Interestingly, a report by Saito et al. showed that nitric ox‐
ide (NO) has an important role in TTR amyloid formation because of the S-nitrosylation of
cysteine 10 of TTR monomers [71].
TTR aggregation can also be triggered by mild acidification (pH 5.0–4.0) [73], cold storage
[74] and the presence of metals such as Zn2+ [72, 75]. Using X-ray crystallography, Palanina‐
than et al. observed that acidic conditions increase the probability that the EF helix–loop of
the B monomer of TTR changes its conformation, leading to destabilisation of the TTR tet‐
ramer and favouring TTR aggregation [73]. In addition, upon further acidification (< pH
3.9), TTR monomers can adopt a different conformation that may not be in the classic fold‐
ing pathway of TTR but is able to aggregate without reaching the amyloid fibril [73]. Olofs‐
son et al. have shown that prior to aggregation, the first step in TTR destabilisation occurs in
the C-D β-strands, which dislocate when exposed to acidic conditions [76]. More data have
shown that not only are the C-D β-strands more susceptible to destabilisation but also the
entire β-sheet sandwich CBEF actually dislocates upon acidification [77], suggesting that
this region of TTR may be responsible, in part, for the first structural changes preceding TTR
dissociation. Recently, Bateman et al. demonstrated that wt-TTR fibril cores were predomi‐
nantly composed of the C-terminal region and described a different pathway of aggregation
that may not require loosening of the above-mentioned TTR regions [78]. Interestingly, the
majority of amyloidogenic mutations, which are associated with FAP, FAC or OA, are found
within the β-strands of the CBEF β-sheet sandwich [77]. Other groups also believe that acid‐
ic conditions may make an important contribution to TTR aggregation both in vitro and in
vivo, in which the amyloid process may take place inside endosomes and lysosomes [79, 80].
Previous data have shown that high concentrations of metals, such as Zn2+ and Cu2+, can in‐
duce TTR amyloid formation in vitro [81]. Additionally, chelating agents, such as EDTA or
EGTA, are able to disrupt amyloid fibrils, suggesting that metals affect the stability of TTR
fibrils [81]. Interestingly, Zn2+ was also found in ex vivo ocular amyloid deposits from FAP
patients, indicating the possible role of metals in the pathogenesis of FAP [82]. Our group
has shown that increasing concentrations of Zn2+ are able to perturb, predominantly under
acidic conditions, the loop EF helix loop, a region involved in RBP binding [75]. This region
has recently been implicated in this phenomenon by two other groups, as the X-ray struc‐
tures of wt-TTR and two variants, I84A and I84S, demonstrated a structural perturbation in
the EF helix loop under acidic conditions [83].
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6. Conclusion
Although many studies have attempted to infer the conditions that affect TTR stability and
amyloidogenicity, why the disease penetrance, pathology and clinical course are so different
between mutations is still not completely understood. Herein, we present some of the data
obtained by different groups that provides evidence on TTR stability and amyloidogenicity.
Many groups have collected data on TTR stability by studying the structure of TTR and de‐
signing TTR-binding compounds. However, as further questions have been raised about
TTR stability, more evidence has demonstrated that most of the answers with regard to TTR
stability lie within its thermodynamic properties and rate of tetramer dissociation.
Acknowledgements
We would like to thank the funding agencies: Conselho Nacional de Desenvolvimento Cien‐
tífico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
(CAPES) and Fundação de Amparo a Pesquisa Carlos Chagas Filho do Estado do Rio de Ja‐
neiro (FAPERJ).
Author details
Estefania Azevedo1, Priscila F. Silva1, Fernando Palhano1,2, Carolina A. Braga1,3 and
Debora Foguel1
1 Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro,
Brazil
2 The Scripps Research Institute, La Jolla, California, USA
3 Polo de Xerem, Universidade Federal do Rio de Janeiro, Duque de Caxias, Brazil
References
[1] Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease.
Annual Review of Biochemistry 2006; 75, 333-366.
[2] Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glims‐
dal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL,
Gandy S, Jucker M, Aguzzi A, Hammarström P, Nilsson KP. Novel pentameric thio‐
Transthyretin-Related Amyloidoses: A Structural and Thermodynamic Approach
http://dx.doi.org/10.5772/53148
123
phene derivatives for in vitro and in vivo optical imaging of a plethora of protein ag‐
gregates in cerebral amyloidoses. ACS Chem Biol. 2009; 4(8):673-84.
[3] Benson MD, Kincaid JC.The molecular biology and clinical features of amyloid neu‐
ropathy. Muscle Nerve. 2007; 36(4):411-23.
[4] Serpell LC, Sunde M, Fraser PE, Luther PK, Morris EP, Sangren O, Lundgren E,
Blake CC. Examination of the structure of the transthyretin amyloid fibril by image
reconstruction from electron micrographs. Journal of Molecular Biology. 1995; 254(2):
113-8.
[5] Hamilton JA, Benson MD. Transthyretin: a review from a structural perspective.Cel‐
lular and Molecular Life Sciences. 2001; 58(10):1491-521.
[6] Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein compo‐
nents in cerebrospinal fluid and their relationship to the serum proteins. Journal of
Clinical Investigation. 1942; 21(5):571-7
[7] Mita S, Maeda S, Shimada K, Araki S. Cloning and sequence analysis of cDNA for
human prealbumin. Biochemica et Biophysica Research Communications. 1984;
124(2):558-64.
[8] Cendron L, Ramazzina I, Percudani R, Rasore C, Zanotti G, Berni R.Probing the evo‐
lution of hydroxyisourate hydrolase into transthyretin through active-site redesign.
Journal of Molecular Biology. 2011; 409(4):504-12.
[9] Liz MA, Faro CJ, Saraiva MJ, Sousa MM. Transthyretin, a new cryptic protease. Jour‐
nal of Biological Chemistry. 2004; 279(20):21431-8.
[10] Said G. Familial amyloid polyneuropathy: mechanisms leading to nerve degenera‐
tion. Amyloid. 2003; 1:7-12.
[11] Blake CC, Swan ID, Rerat C, Berthou J, Laurent A, Rerat B. An x-ray study of the sub‐
unit structure of prealbumin. Journal of Molecular Biology. 1971; 61(1):217-24
[12] Foss TR, Wiseman RL, Kelly JW. The pathway by which the tetrameric protein trans‐
thyretin dissociates. Biochemistry. 2005; 44(47):15525-33.
[13] Silva JL, Cordeiro Y, Foguel D. Protein folding and aggregation: two sides of the
same coin in the condensation of proteins revealed by pressure studies. Biochimica et
Biophysica Acta. 2006; 1764(3):443-51.
[14] Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under par‐
tially denaturing conditions is a downhill polymerization. Biochemistry. 2004;43(23):
7365-81.
[15] Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW..The transthyretin amyloido‐
ses: from delineating the molecular mechanism of aggregation linked to pathology to
a regulatory-agency-approved drug. Journal of Molecular Biology. 2012;421(2-3):
185-203.
Amyloidosis124
[16] Saraiva MJ. Transthyretin mutations in health and disease. Human Mutations.
1995;5(3):191-6.
[17] Ando Y, Suhr OB.Autonomic dysfunction in familial amyloidotic polyneuropathy
(FAP). Amyloid. 1998; 5(4):288-300.
[18] Alves IL, Altland K, Almeida MR, Winter P, Saraiva MJ. Screening and biochemical
characterization of transthyretin variants in the Portuguese population. Human Mu‐
tations. 1997;9(3):226-33.
[19] Tanaka M, Hirai S, Matsubara E, Okamoto K, Morimatsu M, Nakazato M. Familial
amyloidotic polyneuropathy without familial occurrence: carrier detection by the ra‐
dioimmunoassay of variant transthyretin. Journal of Neurology, Neurosurgery and
Psychiatry. 1988; 51(4):576-8.
[20] Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic
amyloidosis is derived from normal transthyretin. Proccedings in National Academy
of Sciences of United States of America. 1990; 87(7):2843-5.
[21] Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to amelio‐
rate the transthyretin amyloidoses. Current Pharmaceuthical Design. 2008;14(30):
3219-30.
[22] Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H.Wild-type trans‐
thyretin-derived amyloidosis in various ligaments and tendons. Human Pathology.
2011;42(9):1259-64.
[23] Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E,
Salvi F, Branzi A.Transthyretin-related amyloidoses and the heart: a clinical over‐
view. Nature Review Cardiology. 2010;7(7):398-408.
[24] Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN.Cardiac transthyretin amyloidosis.
Heart. 2012 Aug 11.
[25] Benson MD. Leptomeningeal amyloid and variant transthyretins. American Journal
of Pathology. 1996;148(2):351-4.
[26] Liepnieks JJ, Dickson DW, Benson MD. A new transthyretin mutation associated
with leptomeningeal amyloidosis. Amyloid. 2011; 18 Suppl 1:155-7.
[27] Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch
WE, Kelly JW.The biological and chemical basis for tissue-selective amyloid disease.
Cell. 2005;121(1):73-85
[28] Hund E, Linke RP, Willig F, Grau A.Transthyretin-associated neuropathic amyloido‐
sis. Pathogenesis and treatment.Neurology. 2001;56(4):431-5.
[29] Liepnieks JJ, Benson MD.Progression of cardiac amyloid deposition in hereditary
transthyretin amyloidosis patients after liver transplantation. Amyloid. 2007;14(4):
277-82.
Transthyretin-Related Amyloidoses: A Structural and Thermodynamic Approach
http://dx.doi.org/10.5772/53148
125
[30] Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropa‐
thy after liver transplantation. Neurology. 2010; 75(4):324-7.
[31] Munar-Qués M, Salva-Ladaria L, Mulet-Perera P, Solé M, López-Andreu FR, Saraiva
MJ.Vitreous amyloidosis after liver transplantation in patients with familial amyloid
polyneuropathy: ocular synthesis of mutant transthyretin.Amyloid. 2000;7(4):266-9.
[32] Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Hoshii Y.
Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipi‐
ents of familial amyloid polyneuropathy liver. Liver Transplantation 2007; 13, 215–
18.
[33] Ammirati E, Marziliano N, Vittori C, Pedrotti P, Bramerio MA, Motta V, Orsini F,
Veronese S, Merlini PA, Martinelli L, Frigerio M.The first Caucasian patient with
p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart
transplantation.Amyloid. 2012;19(2):113-7.
[34] Bartalena, L. & Robbins, J. (1993). Thyroid hormone transport proteins. Clin. Lab.
Med. 13, 583–598.
[35] Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW.Inhibiting transthyre‐
tin amyloid fibril formation via protein stabilization. Procedings of the National
Academy of Sciences of the United States of America. 1996;93(26):15051-6
[36] Cody V.Mechanisms of molecular recognition: crystal structure analysis of human
and rat transthyretin inhibitor complexes. Clinical Chemistry and Laboratory Medi‐
cine. 2002;40(12):1237-43.
[37] Trivella DB, Sairre MI, Foguel D, Lima LM, Polikarpov I.The binding of synthetic
triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative
and non-cooperative ligand recognition. Journal of Structural Biology. 2011;173(2):
323-32
[38] Adamski-Werner SL Palaninathan SK, Sacchettini,JC, Kelly J W. Diflunisal analogues
stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. Jour‐
nal of Medical Chemistry.2004; 47,355–374.
[39] Baures PW, Oza VB, Peterson SA, Kelly JW. Synthesis and evaluation of inhibitors of
transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug,
flufenamic acid. Bioorganic and Medical Chemistry.1999; 7, 1339–1347.
[40] Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ.Small transthyretin (TTR)
ligands as possible therapeutic agents in TTR amyloidoses. Current Drug Targets:
CNS and Neurological Disorders. 2005; 4(5):587-96
[41] Neumann P, Cody V, Wojtczak A.Structural basis of negative cooperativity in trans‐
thyretin. Acta Biochimica Polonica. 2001; 48(4):867-75.
Amyloidosis126
[42] Graham DY, Opekun AR, Willingham FF, Qureshi WA.Visible small-intestinal mu‐
cosal injury in chronic NSAID users. Clinical Gastroenterology and Hepatology.
2005; 3(1):55-9.
[43] Ferreira N, Saraiva MJ, Almeida MR. Natural polyphenols inhibit different steps of
the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters. 2011;
585(15):2424-30.
[44] Trivella DB, Dos Reis CV, Lima LM, Foguel D, Polikarpov I.Flavonoid interactions
with human transthyretin: Combined structural and thermodynamic analysis. Jour‐
nal of Structural Biology. 2012; in press.
[45] Trivella DB, Bleicher L, Palmieri Lde C, Wiggers HJ, Montanari CA, Kelly JW, Lima
LM, Foguel D, Polikarpov I. Conformational differences between the wild type and
V30M mutant transthyretin modulate its binding to genistein: implications to tetram‐
er stability and ligand-binding. Journal of Structural Biology. 2010; 170(3):522-31.
[46] Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amy‐
loid disease. Science. 2001; 293(5539):2459-62.
[47] Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers
ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R. Tafamidis, a potent
and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc‐
cedings of the National Academy of Sciences of the Unites States of America.
2012;109(24):9629-34.
[48] Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V,
Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW,
Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR.Tafamidis for transthyre‐
tin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology.
2012
[49] Benson MD, Pandey S, Witchell D, Jazayeri A, Siwkowski A, Monia B, Kluve-Becker‐
man B. Antisense oligonucleotide therapy for TTR amyloidosis.Amyloid. 2011; 18;
1-55.
[50] Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP.Clinical
development of an antisense therapy for the treatment of transthyretin-associated
polyneuropathy. Amyloid. 2012; 1:43-4.
[51] Hayashi Y, Mori Y, Higashi T, Motoyama K, Jono H, Sah DW, Ando Y, Arima H. Sys‐
temic delivery of transthyretin siRNA mediated by lactosylated dendrimer/α-cyclo‐
dextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy
therapy.Amyloid. 2012; 1:47-9.
[52] Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW,
Monia BP.Suppression of choroid plexus transthyretin levels by antisense oligonu‐
cleotide treatment. Amyloid. 2010;17(2):43-9.
Transthyretin-Related Amyloidoses: A Structural and Thermodynamic Approach
http://dx.doi.org/10.5772/53148
127
[53] Ferrão-Gonzales AD, Souto SO, Silva JL, Foguel D.The preaggregated state of an
amyloidogenic protein: hydrostatic pressure converts native transthyretin into the
amyloidogenic state. Proccedings of the National Academy of Sciences of the United
States of America. 2000;97(12):6445-50.
[54] Cardoso I, Saraiva MJ.Doxycycline disrupts transthyretin amyloid: evidence from
studies in a FAP transgenic mice model. FASEB Journal. 2006; 20(2):234-9.
[55] Gertz MA, Lacy MQ, Dispenzieri A, Cheson BD, Barlogie B, Kyle RA, Palladini G,
Geyer SM, Merlini G. A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin
(IDOX) in primary amyloidosis (AL). Amyloid. 2002; 9(1):24-30.
[56] Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli
I, Marinone MG, Garini P, et al. Interaction of the anthracycline 4'-iodo-4'-deoxydox‐
orubicin with amyloid fibrils: inhibition of amyloidogenesis. Proccedings of the Na‐
tional Academy of Sciences of the United States of America. 1995; 92(7):2959-63.4-9.
[57] Danesi R, Bernardini N, Agen C, Costa M, Macchiarini P, Della Torre P, Del Tacca
M.Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-dox‐
orubicin.Toxicology. 1991;70(2):243-53.
[58] Hörnberg A, Eneqvist T, Olofsson A, Lundgren E, Sauer-Eriksson AE.A comparative
analysis of 23 structures of the amyloidogenic protein transthyretin. Journal of Mo‐
lecular Biology. 2000;302(3):649-69.
[59] Azevedo EP, Pereira HM, Garratt RC, Kelly JW, Foguel D, Palhano FL. Dissecting the
structure, thermodynamic stability, and aggregation properties of the A25T trans‐
thyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying
protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal
fluid. Biochemistry. 2011; 50(51):11070-83.
[60] Ferrão-Gonzales AD, Palmieri L, Valory M, Silva JL, Lashuel H, Kelly JW, Foguel
D.Hydration and packing are crucial to amyloidogenesis as revealed by pressure
studies on transthyretin variants that either protect or worsen amyloid disease. Jour‐
nal of Molecular Biology. 2003;328(4):963-74.
[61] Hamilton JA, Steinrauf LK, Braden BC, Liepnieks J, Benson MD, Holmgren G,
Sandgren O, Steen L. The x-ray crystal structure refinements of normal human trans‐
thyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. Journal of
Biological Chemistry. 1993; 268(4):2416-24.
[62] Sebastião MP, Saraiva MJ, Damas AM. The crystal structure of amyloidogenic Leu55
--> Pro transthyretin variant reveals a possible pathway for transthyretin polymeriza‐
tion into amyloid fibrils.Journal of Biological Chemistry. 1998; 273(38):24715-22.
[63] Karlsson A, Sauer-Eriksson AE. Heating of proteins as a means of improving crystal‐
lization: a successful case study on a highly amyloidogenic triple mutant of human
Amyloidosis128
transthyretin. Acta Crystallographica Section F: Structural Biology and Crystalliza‐
tion Communications. 2007; 63(Pt 8):695-700.
[64] Nakanishi T, Yoshioka M, Moriuchi K, Yamamoto D, Tsuji M, Takubo T. S-sulfona‐
tion of transthyretin is an important trigger step in the formation of transthyretin-re‐
lated amyloid fibril. Biochimica et Biophysica Acta. 2010 ;1804(7):1449-56
[65] Lim A, Prokaeva T, McComb ME, Connors LH, Skinner M, Costello CE.Identification
of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a
patient diagnosed with familial transthyretin amyloidosis. Protein Science. 2003;
12(8):1775-85.
[66] Hagen GA, Elliott WJ. Transport of thyroid hormones in serum and cerebrospinal
fluid.The Journal of Clinical Endocrinology and Metabolism. 1973; 37(3):415-22.
[67] Hou X, Mechler A, Martin LL, Aguilar MI, Small DH. Cholesterol and anionic phos‐
pholipids increase the binding of amyloidogenic transthyretin to lipid membranes.
Biochimica et Biophysica Acta. 2008; 1778(1):198-205.
[68] Cardoso I, Brito M, Saraiva MJ.Extracellular matrix markers for disease progression
and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related.
Disease Markers. 2008; 25(1):37
[69] Bourgault S, Solomon JP, Reixach N, Kelly JW.Sulfated glycosaminoglycans acceler‐
ate transthyretin amyloidogenesis by quaternary structural conversion.Biochemistry.
2011; 15;50(6):1001-15.
[70] Murakami T, Yi S, Maeda S, Tashiro F, Yamamura K, Takahashi K, Shimada K, Araki
S.Effect of serum amyloid P component level on transthyretin-derived amyloid depo‐
sition in a transgenic mouse model of familial amyloidotic polyneuropathy. Ameri‐
can Journal of Pathology. 1992; 141(2):451-6.
[71] Saito S, Ando Y, Nakamura M, Ueda M, Kim J, Ishima Y, Akaike T, Otagiri M.Effect
of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis. Bio‐
chemistry. 2005; 44(33):11122-9.
[72] Bonifácio MJ, Sakaki Y, Saraiva MJ. 'In vitro' amyloid fibril formation from transthyr‐
etin: the influence of ions and the amyloidogenicity of TTR variants. Biochimica et Bi‐
ophysica Acta. 1996; 1316(1):35-42
[73] Palaninathan SK, Mohamedmohaideen NN, Snee WC, Kelly JW, Sacchettini JC.Struc‐
tural insight into pH-induced conformational changes within the native human
transthyretin tetramer. Journal of Molecular Biology. 2008; 382(5):1157-67.
[74] Sörgjerd K, Klingstedt T, Lindgren M, Kågedal K, Hammarström P.Prefibrillar trans‐
thyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in
cell culture. Biochemical and Biophysical Research Communications. 2008; 377(4):
1072-8
Transthyretin-Related Amyloidoses: A Structural and Thermodynamic Approach
http://dx.doi.org/10.5772/53148
129
[75] Palmieri Lde C, Lima LM, Freire JB, Bleicher L, Polikarpov I, Almeida FC, Foguel D.
Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis
and retinol-binding protein recognition. Journal of Biological Chemistry. 2010;
285(41):31731-41
[76] Olofsson A, Ippel JH, Wijmenga SS, Lundgren E, Ohman A.Probing solvent accessi‐
bility of transthyretin amyloid by solution NMR spectroscopy. Journal of Biological
Chemistry. 2004; 279(7):5699-707.
[77] Liu K, Cho HS, Lashuel HA, Kelly JW, Wemmer DE.A glimpse of a possible amyloi‐
dogenic intermediate of transthyretin. Nature Structural Biology. 2000 ;7(9):754-7.
[78] Bateman DA, Tycko R, Wickner RB. Experimentally derived structural constraints for
amyloid fibrils of wild-type transthyretin. Biophysical Journal. 2011; 101(10):2485-92.
[79] Chang MH, Hua CT, Isaac EL, Litjens T, Hodge G, Karageorgos LE, Meikle PJ.Trans‐
thyretin interacts with the lysosome-associated membrane protein (LAMP-1) in cir‐
culation. Biochem J. 2004; 382(Pt 2):481-9.
[80] Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin
amyloid fibril inhibitors in blood plasma. Proccedings of the National Academy of
Sciences of United States of America. 2001; 98(10):5566-71.
[81] Wilkinson-White LE, Easterbrook-Smith SB. Characterization of the binding of Cu(II)
and Zn(II) to transthyretin: effects on amyloid formation. Biochemistry. 2007; 46(31):
9123-32.
[82] Susuki S, Ando Y, Sato T, Nishiyama M, Miyata M, Suico MA, Shuto T, Kai H.Multi-
elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy
patients. Amyloid. 2008; 15(2):108-16.
[83] Pasquato N, Berni R, Folli C, Alfieri B, Cendron L, Zanotti G. Acidic pH-induced con‐
formational changes in amyloidogenic mutant transthyretin. Journal of Molecular Bi‐
ology. 2007; 366(3):711-9
Amyloidosis130
